Loading
companiesCompany
ArriVent BioPharma
ArriVent is a Pennsylvania company developing furmonertinib, an EGFR inhibitor approved in China, for EGFR exon 20 insertion and other uncommon EGFR-mutant lung cancers in global trials.
Also called: ArriVent BioPharma, Inc.ArriVent
Overview
ArriVent BioPharma, based in Newtown Square, Pennsylvania and listed on Nasdaq since 2024, licenses medicines approved in China for development elsewhere. Its lead is furmonertinib (firmonertinib), a third-generation EGFR inhibitor from Allist Pharmaceuticals that is approved in China for EGFR-mutant non-small-cell lung cancer; ArriVent runs the global phase 3 FURVENT trial in EGFR exon 20 insertion mutations, where it holds FDA breakthrough designation. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.
Headquarters
Newtown Square, PA, US
Scorecard
All companies#205of 1244 companies, score 26
- approved products +6
- targets +2
- modalities +2
- regions +1
- registry trials +15
1 approved, 0 in phase 3, 0 earlier, 1 targets, 59 registry studies. Formula on the scorecards page.
Type
Stage
Public
Website
ApprovedSmall-molecule third-generation EGFR TKI
Furmonertinib · Ivesa
Furmonertinib is a Chinese lung cancer pill of the same class as osimertinib, which more than doubled the time before cancer grew compared with gefitinib in the FURLONG trial.
Similar pages
- TrialTo Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy
Shares Furmonertinib, Non-small-cell lung cancer.
- TrialEfficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion
Shares Furmonertinib, Non-small-cell lung cancer.
- TrialIN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC
Shares Furmonertinib, Non-small-cell lung cancer.
- TrialA Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Adv
Shares Furmonertinib, Non-small-cell lung cancer.
- TrialA Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)
Shares Furmonertinib, Non-small-cell lung cancer.
- TrialA Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases
Shares Furmonertinib, Non-small-cell lung cancer.
- TrialFURLONG
Shares Furmonertinib, EGFR, Non-small-cell lung cancer.
- TermEGFR mutation subtypes (exon 19 deletion, L858R, exon 20 insertion, T790M)
Shares Furmonertinib, EGFR, Non-small-cell lung cancer.
cancers
fronts
targets
drugs
ApprovedSmall-molecule third-generation EGFR TKI
Furmonertinib · Ivesa
trials
Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) WithStudy to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants W